Within inner-mitochondrial membranes, TrkAIII was subjected to Omi/HtrA2-dependent cleavage to tyrosine phosphorylated 45C48kDa carboxyl terminal active fragments, localised predominantly in tyrosine kinase-domain mitochondrial matrix orientation
Within inner-mitochondrial membranes, TrkAIII was subjected to Omi/HtrA2-dependent cleavage to tyrosine phosphorylated 45C48kDa carboxyl terminal active fragments, localised predominantly in tyrosine kinase-domain mitochondrial matrix orientation. skipping, associates with advanced stage metastatic disease and post-therapeutic relapse, and in NB models TrkAIII exhibits oncogenic activity and promotes chemotherapeutic resistance [1C8]. The TrkAIII oncoprotein is definitely devoid of the D4 activation-prevention website [1, 9] and several N-glycosylation sites important for cell surface receptor localisation [1, 10]. As a consequence, TrkAIII is not expressed in the cell surface but accumulates within pre-Golgi membranes and at the centrosome, where it exhibits spontaneous ligand-independent activation. Spontaneous intracellular TrkAIII activation Aconine prospects to chronic signaling through the IP3K/Akt but not RAS/MAPK pathway and promotes a more stem cell-like, anaplastic, pro-angiogenic, stress-resistant, genetically unstable, tumourigenic and metastatic phenotype…